Want to see MRNA full AI Analyst Report?
Earnings Data
Report Date
Jul 31, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-2.04Last Year’s EPS
-2.13Same Quarter Last Year
Based on 16 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a predominantly constructive commercial and scientific update: strong Q1 revenue growth (driven by international strategic partnerships), multiple regulatory approvals (including the first flu+COVID combo), meaningful cost reductions (adjusted cash cost down 26% YoY) and continued pipeline advancement across respiratory, oncology and rare diseases. Offsetting these positives were a large, near-term litigation settlement charge recognized in Q1 that materially increased cost of sales and GAAP loss, potential contingent legal exposure (up to $1.3B) with multi‑year timing uncertainty, and expected cash drawdown through 2026. On balance, the company demonstrated operational execution and long‑term value drivers while managing a significant one‑time legal headwind.Company Guidance
Strong Q1 Revenue Beat
Total revenue of $400 million in Q1 2026, coming in above guidance and representing a $300 million increase versus prior year (≈+300% YoY). Geographic mix ~80% international / 20% U.S.
Reiterated 2026 Revenue Growth Target
Company reiterated full-year revenue growth guidance of up to 10% for 2026, supported by long‑term strategic partnerships (UK, Canada, Australia) and continued mNEXSPIKE growth.
Material Cost Discipline and Cash Cost Reduction
Adjusted cash cost decreased 26% YoY in Q1 (excluding the litigation settlement). Company remains on track to achieve ~ $4.2 billion adjusted cash costs for full-year 2026.
Non-GAAP Profitability Improvement
Excluding the litigation settlement, net loss would have been $0.5 billion ($1.18 per share), down over 50% versus prior year, reflecting improved operating performance.
Operating Expense Reductions
R&D expenses fell to $649 million (down 24% YoY) as large Phase III respiratory programs and CMV Phase III wind down; SG&A expenses were $173 million (down 18% YoY), reflecting continued cost discipline.
Regulatory and Clinical Milestones
Secured two EU approvals: mNEXSPIKE (COVID vaccine for 12+) and the world's first flu+COVID combo vaccine (approved in EU for adults 50+). Initiated Phase III for Intismeran in Stage 1 NSCLC (monotherapy arm) and Phase III start for pandemic flu program mRNA-1018; norovirus Phase III fully enrolled for its second Northern Hemisphere season with data expected in 2026.
Product Portfolio Expansion and Approvals
Now have four approved products in infectious disease portfolio (including RSV and COVID products). mRNA-1010 (seasonal flu) has U.S. PDUFA date of August 5, 2026; additional filings planned to expand global access to mNEXSPIKE.
Strong Balance Sheet and Cash Planning
Ended Q1 with $7.5 billion in cash and investments; updated 2026 year-end cash target of $4.5–$5.0 billion and projected capex of $0.2–$0.3 billion, reflecting planned investment and liquidity runway.
MRNA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
MRNA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 01, 2026 | $45.94 | $45.37 | -1.24% |
Feb 13, 2026 | $40.11 | $42.23 | +5.29% |
Nov 06, 2025 | $23.56 | $24.33 | +3.27% |
Aug 01, 2025 | $29.56 | $27.61 | -6.61% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Moderna (MRNA) report earnings?
Moderna (MRNA) is schdueled to report earning on Jul 31, 2026, Before Open (Confirmed).
What is Moderna (MRNA) earnings time?
Moderna (MRNA) earnings time is at Jul 31, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MRNA EPS forecast?
MRNA EPS forecast for the fiscal quarter 2026 (Q2) is -2.04.
